It all started with a vision. Today, Bafna Pharmaceuticals Limited has established a strong presence in the pharmaceutical formulation domain, offering world-class manufacturing services backed by a steadfast commitment to quality and innovation. Over the years, we have built a reputation defined by our robust capabilities, unwavering integrity, sound governance, stringent regulatory compliance, enduring business relationships, and an expanding global footprint.
Our formulation manufacturing plant at Grantlyon, Chennai, is equipped with state-of- the-art facilities and designed to meet the most stringent global regulatory requirements. The plant is EU-GMP, UK-MHRA, and TGA Australia approved, and operates as a 100% Export Oriented Unit (EOU).
We continue to leverage our 30+ years of pharmaceutical manufacturing expertise to drive operational excellence across all functions. Our unwavering focus on quality has fueled significant advancements, including the establishment of a state-of-the-art, in- house Quality Control Laboratory. These strategic investments strengthen our capability to deliver innovative, reliable, and accessible pharmaceutical solutions, ensuring our products consistently meet and exceed global regulatory standards. With these integrated strengths, we are steadily advancing towards our vision of becoming a fully integrated pharmaceutical company, offering a comprehensive, one-stop solution to our customers worldwide.
Bafna is strategically focused on strengthening its market presence across the UK, Europe, Australia, MENA, Sri Lanka, the Philippines, and CIS regions as part of its 18- month growth roadmap. We are also expanding our branded generics and potent molecule portfolios in regulated markets to capture new therapeutic segments and reinforce our position as a trusted global pharmaceutical partner.
We recognize that achieving our vision demands continuous effort and determination. To seize the opportunities, Bafna is committed to strategic planning, expert execution, and professional excellence. We will continue to build on our strengths to achieve our goal of becoming a comprehensive Contract Research and Manufacturing Services (CRAMS) provider for regulated markets.
In recent years, Bafna Pharmaceuticals Limited has gained significant momentum across all key areas globalization, and research & development especially within our focus markets. With the dedication of our entire team, we are determined to explore new opportunities, overcome challenges, and continue to grow from strength to strength.
We also remain deeply committed to our governance and ESG goals. Our ongoing efforts include a focus on reducing our environmental footprint, ensuring ethical practices across our supply chain, and fostering a safe, welcoming, and inclusive workplace. Regulatory compliance remains central to our operations, and our adherence to stringent quality control measures, including our MHRA approval, ensures that every product meets the highest standards.
BAFNA MAHAVEER CHAND
CEO